Cullinan Therapeutics获FDA快速通道认证,推出Cln-049治疗复发/难治性急性髓系白血病

美股速递
Dec 01, 2025

Cullinan Therapeutics获FDA快速通道认证,推出Cln-049,这是一种新型的Flt3xcd3 T细胞引导剂,旨在治疗复发和难治性的急性髓系白血病。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10